Matthieu Dusselier

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Circulating Tumor

Peritoneal Dialysis

Ejection Fraction

Genome Wide Identification

Top Venues

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Patrice Desmeules, Matthieu Dusselier, Cédrik Bouffard, Josée Bafaro, Marc Fortin, Catherine Labbé, Philippe Joubert
Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. Current oncology (Toronto, Ont.) 30 (1) (2023)
Patrice Desmeules, Matthieu Dusselier, Cédrik Bouffard, Josée Bafaro, Marc Fortin, Catherine Labbé, Philippe Joubert
Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. Current oncology (Toronto, Ont.) 30 (1) (2023)
Patrice Desmeules, Matthieu Dusselier, Cédrik Bouffard, Josée Bafaro, Marc Fortin, Catherine Labbé, Philippe Joubert
Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. Current oncology (Toronto, Ont.) 30 (1) (2023)
Patrice Desmeules, Matthieu Dusselier, Cédrik Bouffard, Josée Bafaro, Marc Fortin, Catherine Labbé, Philippe Joubert
Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. Current oncology (Toronto, Ont.) 30 (1) (2023)
Patrice Desmeules, Matthieu Dusselier, Cédrik Bouffard, Josée Bafaro, Marc Fortin, Catherine Labbé, Philippe Joubert
Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. Current oncology (Toronto, Ont.) 30 (1) (2023)
Matthieu Dusselier, Elise Deluche, Nellie Delacourt, Julia Ballouhey, Thomas Egenod, Boris Melloni, Charlotte Vergnenègre, Rémi Veillon, Alain Vergnenègre
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. PloS one 14 (7) (2019)